Clinical trials: Plasma Cell Tumor
AL Amyloidosis, Smoldering Multiple Myeloma
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
The investigators plan to establish a dedicated network of Italian Hematologic Departments interconnected with the Amyloidosis Research and Treatment Center in Pavia to: 1.
- Conditions
- AL Amyloidosis, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- ProDigALIty (NCT06383143)
- Testing
- no intervention
- Where
- 4 sites in Italy
- Volunteers
- 760 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Multiple Myeloma
S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Chemotherapy plus interferon alfa may be effective for primary systemic amyloidosis. PURPOSE: Phase II trial to study the effectiveness of dexamethasone plus interferon alfa in treating patients who have primary…
- Trial name
- NCT00002849
- Testing
- recombinant interferon alfa, dexamethasone
- Where
- 40 sites in United States
- Volunteers
- 93 people
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
- Trial name
- NCT03448978
- Testing
- Descartes-08, Fludarabine, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Cartesian Therapeutics
Multiple Myeloma
QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression
The primary objective is to evaluate when Revlimid and Dexamethasone treatment extend the time to progression to symptomatic MM in patients with smoldering MM.
- Trial name
- QUIREDEX (NCT00480363)
- Testing
- Maintenance with lower doses of lenalidomide and dexamethasone
- Where
- 13 sites in Spain
- Volunteers
- 120 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma, Plasma Cell Leukemia
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of autologous stem cell transplantation combined with BCMA CAR-T therapy followed by GPRC5D/CD3 bispecific antibody maintenance in…
- Trial name
- CAREMM-004 (NCT07106684)
- Testing
- Autologous hematopoietic stem cell transplantation, BCMA CAR-T, GPRC5D/CD3 BiTEs
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
Study a quadruplet-based regimen with Minimal Residual Disease (MRD) 10-5 negative rate as primary end point in patients with early Relapsed or Refractory Multiple Myeloma.
- Trial name
- NCT04287855
- Testing
- Isatuximab, Carfilzomib, Pomalidomide
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Poitiers University Hospital
Multiple Myeloma, Hematopoietic Stem Cell Mobilization
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
This is a prospective, randomized, two-arm, multicenter, exploratory study aimed at evaluating the efficacy and safety of the combination of etoposide, cytarabine and Pegfilgrastim (EAP regimen) for mobilizing hematopoietic stem…
- Trial name
- NCT06520176
- Testing
- Etoposide, Cytarabine, Pegfilgrastim
- Where
- 16 sites in China
- Volunteers
- 99 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Multiple Myeloma
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and cyclophosphamide with dexamethasone (Car-Cy-Dex) prior to autologous stem cell transplant…
- Trial name
- 11-MM-01 (NCT01660750)
- Testing
- Carfilzomib, Cyclophosphamide, Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Criterium, Inc.
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving radiation therapy and chemotherapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004132
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Lymphoma, Non Hodgkin's Lymphoma
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).
Some patients with multiple myeloma or lymphoma will need treatment with high dose chemotherapy to treat their condition. This potent treatment will kill many of the blood-forming cells in the bone marrow.
- Conditions
- Lymphoma, Non Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
- Trial name
- NCT00665314
- Testing
- Plerixafor (AMD3100), Can be any registered nonpegylated form of G-CSF
- Where
- 5 sites in Germany
- Volunteers
- 5 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Myeloma, CLL
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
This study seeks to examine the investigational use of the conditioning regimen (bendamustine, fludarabine, and rituximab) prior to haploidentical peripheral blood allogeneic stem cell transplantation with Post-Transplant…
- Conditions
- Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia, Lymphoma
- Trial name
- NCT03524235
- Testing
- Total Body Irradiation, Haploidentical Stem Cell Transplantation, CD56-Enriched Donor Lymphocyte Infusion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Noah Merin
Multiple Myeloma
A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma
The aim of this study is to confirm the comparability of the efficacy and safety profiles of BCD-264 and Darzalex as monotherapy for relapsed and refractory multiple myeloma in subjects previously treated with proteasome…
- Trial name
- DARVIVA (NCT06296121)
- Testing
- BCD-264, Darzalex
- Where
- 14 sites in Russia
- Volunteers
- 252 people
- Sponsor
- Biocad
Solid Tumor
PRECISE CURATE.AI Pilot Clinical Trial
In the current clinical context, drug dosing in oncology is dictated by toxicity. The optimal dosages of drugs in combinatory regimens for solid tumours are not clear, and the typical physician's decision on dose adjustment is a…
- Trial name
- NCT04522284
- Testing
- CURATE.AI, Capecitabine, XELOX
- Where
- 2 sites in Singapore
- Volunteers
- 20 people
- Sponsor
- National University Hospital, Singapore
Covid19, Myeloma Multiple
Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden
This retrospective observational cohort study aims to describe the impact of COVID-19 in patients treated with autologous stem cell transplantation (ASCT) for malignant disease in terms of risk factors, morbidity, need for…
- Conditions
- Covid19, Myeloma Multiple, Malignant Lymphoma, Hematologic Neoplasms
- Trial name
- AutoCOVID-19 (NCT04760184)
- Testing
- Autologous stem cell transplantation
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Uppsala University
Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
- Conditions
- Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03844048
- Testing
- Venetoclax
- Where
- 56 sites in United States, Australia and 21 more
- Volunteers
- 165 people
- Sponsor
- AbbVie
Multiple Myeloma
A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients
The purpose of this study is to determine whether the orthostatic hypotension reported among subjects during bortezomib-containing regimen is caused by a dysfunction of the autonomic nervous system (ANS).
- Trial name
- NCT01314625
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Arkansas
Myeloma
Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine
The purpose of this study is to determine the feasibility of giving (i) rapamycin or (ii) hydroxychloroquine (HCQ), with standard doses of infusional cyclophosphamide and pulse dexamethasone (cy/dex) for patients with…
- Trial name
- NCT01396200
- Testing
- Hydroxychloroquine, Rapamycin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Multiple Myeloma
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
To assess the safety and tolerability, characterize the dose limiting toxicities (DLTs) and identify the maximally tolerated dose (MTD) of Elotuzumab administered in combination with either Lirilumab or Urelumab in subjects with…
- Trial name
- NCT02252263
- Testing
- Elotuzumab, Lirilumab, Urelumab
- Where
- 7 sites in United States, Spain
- Volunteers
- 44 people
- Sponsor
- Bristol-Myers Squibb
Relapsed/Refractory Multiple Myeloma
A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
The primary objectives of this study are to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and the recommended phase two dose (RPTD) of ABT-199 when…
- Trial name
- NCT01794507
- Testing
- ABT-199, bortezomib, dexamethasone
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 66 people
- Sponsor
- AbbVie
Multiple Myeloma
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and efficacy of allogeneic anti-BCMA/GPRC5D bispecific chimeric antigen receptor natural killer (CAR-NK) cells (ACT-001) in patients with…
- Trial name
- NCT06594211
- Testing
- ACT-001 CAR-NK cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- RenJi Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.